These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 29277796)

  • 21. Quantitation of HER2/neu expression in primary gastroesophageal adenocarcinomas using conventional light microscopy and quantitative image analysis.
    Jeung J; Patel R; Vila L; Wakefield D; Liu C
    Arch Pathol Lab Med; 2012 Jun; 136(6):610-7. PubMed ID: 22646266
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HER2 Genetic Heterogeneity in Gastric Cancer: Evaluation According to the College of American Pathologists Breast Cancer Criteria.
    Treacy AD; Karamchandani JR; Streutker CJ; Grin A
    Appl Immunohistochem Mol Morphol; 2015 Oct; 23(9):628-32. PubMed ID: 25611242
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HER2 status in lung adenocarcinoma: a comparison of immunohistochemistry, fluorescence in situ hybridization (FISH), dual-ISH, and gene mutations.
    Yoshizawa A; Sumiyoshi S; Sonobe M; Kobayashi M; Uehara T; Fujimoto M; Tsuruyama T; Date H; Haga H
    Lung Cancer; 2014 Sep; 85(3):373-8. PubMed ID: 25047676
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevalence of HER2 Expression and Its Correlation with Clinicopathological Parameters in Gastric or Gastroesophageal Junction Adenocarcinoma in North-East Indian Population.
    Roy PS; Nyodu T; Hazarika M; Saikia BJ; Bhuyan C; Inamdar A; Nyuthe CW; Borthakur B; Sharma JD
    Asian Pac J Cancer Prev; 2019 Apr; 20(4):1139-1145. PubMed ID: 31030487
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HER2 expression and relevant clinicopathological features in esophageal squamous cell carcinoma in a Chinese population.
    Rong L; Wang B; Guo L; Liu X; Wang B; Ying J; Xue L; Lu N
    Diagn Pathol; 2020 Mar; 15(1):27. PubMed ID: 32209107
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma.
    Bozzetti C; Negri FV; Lagrasta CA; Crafa P; Bassano C; Tamagnini I; Gardini G; Nizzoli R; Leonardi F; Gasparro D; Camisa R; Cavalli S; Silini EM; Ardizzoni A
    Br J Cancer; 2011 Apr; 104(9):1372-6. PubMed ID: 21487407
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of Specimen Type and Specimen Number on HER2 Status in Gastroesophageal Junction and Gastric Adenocarcinoma.
    Huber AR; Buscaglia B; Koltz BR; Henry J; McMahon L; Guo J; Hicks DG; Whitney-Miller CL
    Am J Clin Pathol; 2019 Apr; 151(5):461-468. PubMed ID: 30624589
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of HER2 status between surgically resected specimens and matched biopsy specimens of gastric intestinal-type adenocarcinoma.
    Yoshida H; Yamamoto N; Taniguchi H; Oda I; Katai H; Kushima R; Tsuda H
    Virchows Arch; 2014 Aug; 465(2):145-54. PubMed ID: 24889042
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HER2/neu (ERBB2) expression and gene amplification correlates with better survival in esophageal adenocarcinoma.
    Plum PS; Gebauer F; Krämer M; Alakus H; Berlth F; Chon SH; Schiffmann L; Zander T; Büttner R; Hölscher AH; Bruns CJ; Quaas A; Loeser H
    BMC Cancer; 2019 Jan; 19(1):38. PubMed ID: 30621632
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Validation and workflow optimization of human epidermal growth factor receptor 2 testing using INFORM HER2 dual-color in situ hybridization.
    Lim SJ; Cantillep A; Carpenter PM
    Hum Pathol; 2013 Nov; 44(11):2590-6. PubMed ID: 24075600
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomized, Phase II Study of Trastuzumab Beyond Progression in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer: WJOG7112G (T-ACT Study).
    Makiyama A; Sukawa Y; Kashiwada T; Kawada J; Hosokawa A; Horie Y; Tsuji A; Moriwaki T; Tanioka H; Shinozaki K; Uchino K; Yasui H; Tsukuda H; Nishikawa K; Ishida H; Yamanaka T; Yamazaki K; Hironaka S; Esaki T; Boku N; Hyodo I; Muro K
    J Clin Oncol; 2020 Jun; 38(17):1919-1927. PubMed ID: 32208960
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Human epidermal growth factor receptor 2 overexpression in gastric and gastroesophageal junction adenocarcinoma in patients seen at the University Teaching Hospital, Lusaka, Zambia.
    Kasochi C; Julius P; Mweemba I; Kayamba V
    Afr Health Sci; 2020 Dec; 20(4):1857-1864. PubMed ID: 34394249
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HER2 Status in Gastroesophageal Adenocarcinomas: Correlation Between Immunohistochemistry and Fluorescence In Situ Hybridization Methodologies.
    Robertson SA; Cimino-Mathews A; Cornish TC
    Appl Immunohistochem Mol Morphol; 2018 Jan; 26(1):35-39. PubMed ID: 27153447
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HER2 testing in gastric cancer: An update.
    Abrahao-Machado LF; Scapulatempo-Neto C
    World J Gastroenterol; 2016 May; 22(19):4619-25. PubMed ID: 27217694
    [TBL] [Abstract][Full Text] [Related]  

  • 35.
    Zhang L; Hamdani O; Gjoerup O; Cho-Phan C; Snider J; Castellanos E; Nimeiri H; Frampton G; Venstrom JM; Oxnard G; Klempner SJ; Schrock AB
    JCO Precis Oncol; 2022 Jan; 6():e2100330. PubMed ID: 35050711
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gene protein detection platform--a comparison of a new human epidermal growth factor receptor 2 assay with conventional immunohistochemistry and fluorescence in situ hybridization platforms.
    Stålhammar G; Farrajota P; Olsson A; Silva C; Hartman J; Elmberger G
    Ann Diagn Pathol; 2015 Aug; 19(4):203-10. PubMed ID: 25921313
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Pembrolizumab with trastuzumab and chemotherapy in advanced or metastatic gastric or gastroesophageal junction adenocarcinomas with surexpression of HER2 and CPS≥1].
    Lévêque I; Spitzer E
    Bull Cancer; 2024 Feb; 111(2):130-132. PubMed ID: 38071114
    [No Abstract]   [Full Text] [Related]  

  • 38. Clinicopathological features and endoscopic findings of HER2-positive gastric cancer.
    Oono Y; Kuwata T; Takashima K; Yoda Y; Ikematsu H; Shitara K; Kinoshita T; Yano T
    Surg Endosc; 2018 Sep; 32(9):3964-3971. PubMed ID: 29500656
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An analysis of HER2 amplification in cervical adenocarcinoma: correlation with clinical outcomes and the International Endocervical Adenocarcinoma Criteria and Classification.
    Shi H; Shao Y; Lu W; Lu B
    J Pathol Clin Res; 2021 Jan; 7(1):86-95. PubMed ID: 33089969
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Incidence, clinicopathological features, and clinical outcomes of low HER2 expressed, inoperable, advanced, or recurrent gastric/gastroesophageal junction adenocarcinoma.
    Nakayama I; Takahari D; Chin K; Wakatsuki T; Takamatsu M; Yamamoto N; Ogura M; Ooki A; Fukuda K; Osumi H; Fukuoka S; Shinozaki E; Yamaguchi K
    ESMO Open; 2023 Aug; 8(4):101582. PubMed ID: 37348349
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.